“…The glycan chains of the central mucin domain of ␣-dystroglycan are known to mediate binding to components such as laminin (Ervasti and Campbell, 1993), perlecan (Peng et al, 1998) agrin (Bowe et al, 1994;Campanelli et al, 1994;Gee et al, 1994), neurexin in the brain (Sugita et al, 2001) and pikachurin in the eye (Sato et al, 2008). Aberrant glycosylation of ␣-dystroglycan is thought to be central to the pathogenesis of the muscular dystrophy and the brain abnormalities manifested by patients (cobblestone lissencephaly) and animal models with severe forms of dystroglycanopathy (Michele et al, 2002;Michele and Campbell, 2003;Hewitt, 2009;Yoshida-Moriguchi et al, 2010).…”